Background: EORTC 24971 was a phase III trial demonstrating superiority of induction regimen TPF (docetaxel, cisplatin, 5-fluorouracil) over PF (cisplatin/5-fluorouracil), in terms of progression-free (PFS) and overall survival (OS) in locoregionally advanced unresectable head and neck squamous cell carcinomas. We conducted a retrospective analysis of prospectively collected data aiming to evaluate whether only HPV(À) patients (pts) benefit from adding docetaxel to PF, in which case deintensifying induction treatment in HPV(þ) pts could be considered.
Background: EORTC 24971 was a phase III trial demonstrating superiority of induction regimen TPF (docetaxel, cisplatin, 5-fluorouracil) over PF (cisplatin/5-fluorouracil), in terms of progression-free (PFS) and overall survival (OS) in locoregionally advanced unresectable head and neck squamous cell carcinomas. We conducted a retrospective analysis of prospectively collected data aiming to evaluate whether only HPV(À) patients (pts) benefit from adding docetaxel to PF, in which case deintensifying induction treatment in HPV(þ) pts could be considered.
Patients and methods: Pretherapy tumor biopsies (blocks or slides) were assessed for high-risk HPV by p16 immunohistochemistry, PCR and quantitative PCR. HPV-DNAþ and/or p16þ tumors were subjected to in situ hybridization (ISH) and HPV E6 oncogene expression qRT-PCR analysis. Primary and secondary objectives were to evaluate the value of HPV/p16 status as predictive factor of treatment benefit in terms of PFS and OS. The predictive effect was analyzed based on the model used in the primary analysis of the study with the addition of a treatment by marker interaction term and tested at two-sided 5% significance level.
Results: Of 358, 119 pts had available tumor samples and 58 of them had oropharyngeal cancer. Median follow-up was 8.7 years. Sixteen of 119 (14%) evaluable samples were p16þ and 20 of 79 (25%) evaluable tumors were HPV-DNAþ. 13 of 40 pts (33%) assessed with HPV-DNA ISH and 12 of 28 pts (43%) assessed for HPV E6 mRNA were positive. The preplanned analysis showed no statistical evidence of predictive value of HPV/p16 status for PFS (P ¼ 0.287) or OS (P ¼ 0.118).
Introduction
Head and neck squamous cell carcinomas (HNSCC) is expected to account for approximately 740 000 new cases and 410 000 deaths worldwide, for the year 2015 [1] . In Europe, HNSCC incidence and mortality rates are higher compared with the United States, with approximately 140 000 new cases diagnosed in 2014, corresponding to an annual incidence of 43/100 000 [2] . Tobacco and alcohol use account for the vast majority of HNSCC. Human papillomavirus (HPV) infection has been more recently identified as the cause of a distinct subset of HNSCC that arise primarily in the oropharynx [3] . In particular, human papillomavirus type 16 (HPV16) is responsible for >90% of HPV-positive (HPV(þ)) OPSCC [4] .
Accumulating evidence clearly suggests that HPV-associated OPSCC represent a distinct entity in terms of epidemiology, biology, and clinical behavior. Multiple methods for determination of HPV status are available. HPV DNA detection in tumors per se cannot prove causal association as HPV is ubiquitously present in humans. HPV DNA PCR is a sensitive but not a specific method for determination of HPV status. Immunohistochemistry (IHC) for p16 protein expression is used as a surrogate marker of HPV infection in OPSCC. A negative autoregulatory loop between p16 and pRb has been described [5] and degradation of pRb by HPV E7 oncoproteins leads to p16 upregulation in HPV(þ) cancers. p16 IHC followed by PCR for HPV DNA has been proposed as a reliable algorithm for detection of HPV in paraffin-embedded OPSCC specimens. p16 protein expression, however, is not a reliable surrogate marker for HPV infection outside the oropharynx. HPV DNA in situ hybridization (ISH) can differentiate between integrated and episomal forms of HPV in tumors but lacks sensitivity. The gold standard is detection of E6/E7 mRNA, but this may be less sensitive depending on the quality of the clinical sample. In addition, many HPV(þ) patients identified in the next-generation sequencing study by Parfenov et al. [6] had low expression or absence of E6/E7 expression and could be misclassified by E6/E7 mRNA detection [7] .
HPV(þ) OPSCC has a significantly better prognosis independent of stage at diagnosis compared with their HPV(À) counterpart [8] . The risk of death for HPV(þ) patients is consistently <60% that of HPV(À) cancers across studies and the absolute survival difference is consistently higher than 30%. Deintensification research strategies that aim to reduce treatment-related morbidity and improve patient quality of life without compromising treatment effectiveness are being tested in clinical trials. Patients with HPV(þ) OPSCC are young and expected to live long, therefore, morbidity resulting from late toxicity is a concern in these patients. To that extent, in the present study, our aim was to evaluate whether only HPV(À) patients derive benefit from adding docetaxel to PF, in which case deintensifying induction treatment in HPV(þ) patients could be considered. 
Materials and methods
Subjects and collection of biological material EORTC 24971 randomized 358 patients with primary inoperable nonmetastatic HNSCC between TPF (docetaxel, cisplatin, 5-fluorouracil) chemotherapy and PF (cisplatin/5-fluorouracil) induction chemotherapy followed by radiotherapy and demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with the addition of docetaxel to PF [9] . Samples have been collected in the frame of the EORTC 24971 study from 1999 to 2002.
The two main challenges to conduct the retrospective translational research (TR) study were (i) to get a clear view on the available materialas the research was not planned at the time of the protocol and (ii) to get Ethical Committees approval for this research while the patient information sheet/inform consent did not mention any kind of biological material collection (in the frame of planned nor unplanned/future research).
In order to solve the first point, feasibility was conducted among the participating sites, from 2009 to 2011. In 2011, 14 sites answered positively to the request (corresponding to 209 patients) and 5 sites answered negatively (e.g. tissue samples not available anymore). Regarding the second point, most of the ECs did not have any specific requests (patient reconsent, etc). In France, the initial EC feedback required a declaration of biological collection, with abstention of ministerial approvals and patients reconsent/special derogation for deceased patients. Finally, the collection was possible as the EC agreed to the collection for deceased or lost in follow-up patients, without derogations and without ministerial approvals. In total, 4 years were dedicated to the operational part of setting-up this TR project, covering the feasibility, the EC submission and approval processes, and the sample shipment.
We managed to collect 119 HNSCC tissue samples which were assessed for high-risk HPV infection by p16 IHC, PCR and quantitative PCR (qPCR). HPV DNAþ and/or p16þ tumors were subjected to ISH and HPV E6 oncogene expression analysis by qRT-PCR.
Assays IHC staining for p16
IHC was carried out to determine p16 expression using a p16 mouse monoclonal antibody (predilute, mtm-CINtech, E6H4) as described previously [10] . p16 was considered to be positive when defined as strong and diffuse nuclear and cytoplasmic staining in !70% of the tumor cells, which is the same scoring criteria used by Ang et al. [10] .
DNA extraction from paraffin sections
Two 10-lm paraffin sections from HNSCC specimens were used for DNA extraction by the QIAamp DNA FFPE Tissue kit (Qiagen, Hilden, Germany), according to manufacturer's instructions. The DNA was eluted in QIAGEN ATE buffer and stored at À20 C until analysis.
Detection of high-risk HPV DNA by PCR
For high-risk HPV DNA detection, the two most popular worldwide consensus PCR reactions were used: the MY system [11] and the GPþ system [12] both amplifying regions of HPV L1 gene. DNA integrity was assessed by PCR amplification of b-globin with PC04 and GH020 primers [11] . PCR reactions were carried out in the GENEAmp PCR System 9600 (Applied Biosystems, Foster City, CA, USA). The protocols for the PCR detection of high-risk HPV DNA are provided in supplementary S1, available at Annals of Oncology online.
HPV RFLP typing
In case of a positive sample in the MY and/or GPþ PCR system, reactions were carried out again in quadruplicate, mixed and their product was subjected to restriction fragment polymorphism analysis using the BamHI, DdeI, HaeIII, HinfI, PstI, and RsaI restriction enzymes (New England Biolabs, Ipswich, MA, USA). Analysis was carried out in 2% Nusieve 1:1 agarose gel as reported previously [13] . Assignment of an HPV type to a particular risk category was done according to Munoz et al. [14] . The protocols for HPV RGLP typing are provided in supplementary S1, available at Annals of Oncology online.
RT-qPCR for detection of HPV16, 18, and 31
In case of negative samples in MY PCR system, novel RT-qPCR assays were developed in order to provide a more sensitive detection for those HPV types most commonly found in oropharyngeal cancers; types HPV16, 18, and 31. The qPCR primers used amplify a 93bp HPV16 E6 region [15] , a 185 bp HPV18 E1 region [16] and a 350 bp HPV31 E6 region (in-house assay). The protocols for RT-qPCR detection of HPV16, 18, and 31 are provided in supplementary S1, available at Annals of Oncology online.
RNA extraction from hematoxylin and eosinstained slides RNA was extracted from hematoxylin and eosin-stained slides using High Pure FFPET RNA Isolation Kit (Roche, Mannheim, Germany), according to manufacturer's instructions. The RNA was eluted in ROCHE Elution buffer and stored at À80 C until analysis.
cDNA synthesis cDNA synthesis was carried out using the SuperScript TM First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, MA, USA) according to manufacturer's protocol. Additional information for cDNA synthesis is provided in supplementary S1, available at Annals of Oncology online.
HPV in situ hybridization
High-risk HPV status was determined by ISH using a cocktail probe that detects HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66 (GenPoint HPV probe cocktail; Dako, Carpinteria, CA). HPV ISH was interpreted as positive when nuclear-specific staining was detected in the tumor cells. The protocols for HPV ISH are provided in supplementary S1, available at Annals of Oncology online.
Detection of HPV E6 mRNA on paraffin-embedded tissue
Novel SYBR Green-based qPCR assays were developed for the detection of E6 mRNA expression of HPV16, 18, and 31 on FFPE samples. The specific qPCR primers used give rise to a 109bp HPV16-specific and a 131-bp HPV18-specific amplicons, as described previously [17, 18] . Novelspecific primers for HPV31 E6 gene expression were designed giving rise to a 165-bp specific amplicon. GAPDH and b-actin were used as our assays endogenous reference genes. The protocols for the RT-qPCR detection of HPV16, 18, and 31 E6 expression are provided in supplementary S1, available at Annals of Oncology online.
Statistical methods
PFS and OS curves by treatment and marker strata were produced using the Kaplan-Meier method. PFS and OS were based on the long-term survival analysis produced in 2011 [19] . Statistical significance of predictive effects was assessed based on the model used in the primary analysis of the study with the addition of a treatment by marker interaction term. This was a multivariate Cox proportional hazards model with treatment, marker and treatment by marker interaction effects, adjusted for the following covariates: location of primary tumor (oral cavity, oropharynx, or hypopharynx), clinical tumor stage (T), regional-node stage (N), and WHO score for performance status. For the two initially planned analyses, the treatment by marker interaction was tested at a two-sided 5% significance level. The estimate of the hazard ratio for treatment in each marker strata was provided with its 95% confidence interval. For the additional analyses (22 statistical tests), the Benjamini-Hochberg method was applied to control the false discovery rate (FDR). Additional information is provided in supplementary S1, available at Annals of Oncology online.
Results

Patient population
A total 119 tissue samples were obtained from 119 of the 358 patients included in EORTC 24971 study and assessed for p16/HPV markers. Eighty two samples were FFPE blocks and 37 were FFPE slides; Median follow-up for these 119 patients was 8.7 years. The baseline characteristics of these patients are shown in supplementary Table S1 , available at Annals of Oncology online. Patients selected for this project did not differ significantly from the rest of patients with respect to age, gender, tumor site, T stage, nodal stage, although baseline performance status was better, as assessed by t-test for age and from Fisher's exact test for binary or categorical variables. Kaplan-Meier curves of PFS and OS by treatment arm for the 119 patients are shown in Figure 1 .
p16 immunohistochemistry
One hundred nineteen specimens were evaluable for p16 by immunohistochemistry. Sixteen of the 119 patients were positive for p16: The incidence of p16 positivity in the cohort was 13.4% (95% CI: 7.9% to 20.9%). The distribution of p16 positivity by tumor site is shown in Table 1 .
Detection of high-risk HPV DNA by PCR
Seventy-nine of 82 FFPE were evaluable for HPV DNA by PCR. All samples were subject to histopathological evaluation, DNA quality control, and HPV DNA detection. Twenty of 79 FFPE (25.3%, 95% CI: 16.2% to 36.4%) specimens were positive for high-risk HPV DNA (Table 1) 
HPV in situ hybridization
HPV ISH using a set of probes for high-risk HPV detection was carried out both in cases that had slides instead of FFPEs and in cases with positive status for either p16 or HPV DNA by PCR. Forty-one samples met these criteria and 13 of those were HPV(þ) by ISH (32.5%, 95% CI 18.6% to 49.1%) ( Table 1) .
Detection of HPV E6 mRNA on FFPE
HPV DNAþ and/or p16þ tumors were subjected to HPV E6 oncogene expression analysis by qRT-PCR. Twenty-eight samples were evaluable for high-risk HPV RNA analysis by qRT-PCR and 12 of them (11 for HPV16 and 1 for HPV18) were positive for HPV E6 mRNA (42.9%, 95% CI 24.5% to 62.8%).
Predictive effect of HPV status
The preplanned analysis showed no statistical evidence of predictive value of p16/HPV DNA by PCR status for PFS (P ¼ 0.287) or OS (P ¼ 0.118). Kaplan-Meier curves are shown in Figure 1 .
The additional analyses, adjusted for multiplicity to control FDR, showed no statistical evidence of a prognostic or predictive effect; on PFS or OS; based on either markers; in all tumors or restricted to oropharynx.
Discussion
In the present study, we sought to evaluate whether only HPV(À) patients derive benefit from adding docetaxel to PF in induction chemotherapy, in which case deintensifying induction treatment in HPV(þ) patients could be considered. We analyzed pretreatment specimens from patients enrolled in EORTC 24971, a phase III study demonstrating superiority of induction regimen TPF over PF in terms of progression-free (PFS) and overall survival (OS) in locoregionally advanced unresectable HNSCC [9] , for HPV status. The magnitude of the treatment effect found overall was not statistically different in p16/HPV-positive or -negative patients. However, this was a prospective -retrospective analysis only powered to detect a large treatment by marker interaction.
Our primary and secondary objectives were to evaluate the value of HPV/p16 status as predictive factor of treatment benefit in terms of PFS and OS, respectively. The study was designed in 2008 and at that time p16 immunohistochemistry followed by HPV DNA PCR in p16 positive cases had been demonstrated to be a reliable algorithm for a biologically and clinically relevant HPV infection in OPSCC. We therefore presumed that the same algorithm could be used for HPV detection in non-OPSCC. However, it was subsequently shown that p16 protein expression is not a reliable surrogate marker for HPV infection outside the oropharynx [20] . Our study population consisted of both OPSCC and non-OPSCC. We therefore carried out HPV ISH and HPV E6 expression analysis in HPV DNAþ and/or p16þ cases. We found that the incidence of HPV was low in our EORTC 24971 cohort. The study was conducted between April 1999 and March 2002 and our findings are consistent with other studies examining the incidence of HPV infection in European populations during the same time period [21] [22] [23] [24] .
We found that 8 of 20 HPV DNAþ FFPEs contained HPV16, 1 HPV18, 7 HPV31, 3 had infection with both HPV16 and HPV31, and 1 was unspecified. Of the 28 HPV DNAþ and/or p16þ samples analyzed, expression of E6 oncogene detected in 12 samples, of which 11 samples were positive for HPV16 E6 and 1 sample positive for HPV18 E6 expression. In the study by Bratman et al. [25] , the presence of HPV was determined for 515 HNSCCs from TCGA. Seventy-three tumors contained HPV transcripts, among which 61 (84%) were HPV16, and 12 (16%) were HPV-other (8 HPV33, 3 HPV35, and 1 HPV56). The authors reported that HNSCCs harboring HPV genotypes other than HPV16 have inferior survival. However, p16 status was not available for all cases with HPV-other genotypes; a prospective study of HPV-other genotype in OPSCC, uniformly characterized with p16 staining and tobacco history, and uniformly treated, is required before concluding that HPV-other genotypes confer poor prognosis in HNSCC.
In addition to oropharynx, the subsite for which HPV carcinogenesis is best understood, our study also included oral cavity, larynx and hypopharynx. In the study of 3680 cases of HNSCC by Castellsagué et al. [26] the incidence of HPV positivity was 22.4%, 4.4%, and 3.5% for cancers of the oropharynx, oral cavity, and larynx, respectively. HPV16 was the dominant genotype. In our study the incidence of HPV/p16 double positive was 6/10, 1/22, 1/7, and 2/ 32 in oropharynx, oral cavity, larynx, and hypopharynx respectively.
Our retrospective study was only powered to detect a large treatment by marker interaction. The study data did not show 
